Seminal work on CRISPR-Cas9 published in 2012 led to an explosion of interest in the gene editing field. As pioneers in CRISPR-Cas9 enabled genome editing, Sigma-Aldrich® scientists, Greg Davis and Fuqiang Chen, showed how CRISPR-Cas9 could be efficiently tailored for the specific placement of a gene or gene fragment within the genome. This approach to genome editing, utilizing the innate DNA repair pathways such as homology-directed repair in particular, can result in more effective gene and CAR-T therapies and greater efficiencies in plant trait expressions to name just a few uses, while preserving the normal functioning of the original genome. This invention provided a method for integrating an exogenous nucleic acid sequence into a chromosomal sequence of a eukaryotic cell either in vivo, ex vivo or in vitro.
The CRISPR IP landscape is complex with no single entity owning all the rights in all the territories. Our foundational invention and patents cover nucleic acid integration using CRISPR-Cas9 which can be used in gene editing for (a) correction or disabling of genes when developing gene or cell therapies, or (b) adding genes for producing desired traits in plants for example, as well as many other applications.
Sigma-Aldrich Co LLC has received over 55 patents including on its CRISPR-based eukaryotic genomic editing applications deriving from International Application No. PCT/US2013/073307 in the following territories:
We also have pending patent applications for its CRISPR mediated insertion method in Brazil, India, and Japan.
In addition to its foundational patents on CRISPR mediated integration of an exogenous DNA molecule into a eukaryotic chromosome, our patents cover the following methods and compositions:
We are a leader in developing innovative genome editing tools and technologies such as CRISPR and promoting its translation into genomic medicines to benefit patients and plant engineering to better sustain the world’s population.
However, we also recognise that no single organization can pursue every avenue with respect to gene editing research and development. As a result, we are committed to democratizing this foundational technology by making our CRISPR patent estate available for license to help ensure that the resulting scientific developments have the best chance of success. To that end we will:
To date, we have licensed out foundational CRISPR patents to various organizations including but not limited to Promega, genOway, Evotec, Horizon Discovery (a Perkin Elmer company), Abcam, Integrated DNA Technologies, Life Technologies (a ThermoFisher company), Cellecta, BetterSeeds, PanCELLa, Takara Bio and many others.
To enable access to this foundational platform technology, we offer licenses to our CRISPR patent estate to both commercial and non-profit organizations. We look forward to hearing from you and welcome your interest in our IP. Please address all licensing inquiries to: